Share on StockTwits

Investment analysts at Jefferies Group upped their price target on shares of PAREXEL International (NASDAQ:PRXL) from $58.00 to $59.00 in a note issued to investors on Thursday. Jefferies Group’s price objective indicates a potential upside of 8.60% from the stock’s previous close.

A number of other firms have also recently commented on PRXL. Analysts at KeyCorp initiated coverage on shares of PAREXEL International in a research note on Wednesday, July 2nd. They set a “hold” rating on the stock. Separately, analysts at Wells Fargo & Co. upgraded shares of PAREXEL International to a “priority list” rating in a research note on Thursday, June 26th. Finally, analysts at Zacks upgraded shares of PAREXEL International from a “neutral” rating to an “outperform” rating in a research note on Thursday, June 26th. They now have a $58.20 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $55.80.

Shares of PAREXEL International (NASDAQ:PRXL) opened at 54.33 on Thursday. PAREXEL International has a one year low of $37.53 and a one year high of $57.25. The stock’s 50-day moving average is $53.88 and its 200-day moving average is $51.6. The company has a market cap of $3.090 billion and a P/E ratio of 26.25.

PAREXEL International (NASDAQ:PRXL) last released its earnings data on Thursday, August 7th. The company reported $0.65 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.62 by $0.03. The company had revenue of $510.60 million for the quarter, compared to the consensus estimate of $508.99 million. During the same quarter last year, the company posted $0.50 earnings per share. PAREXEL International’s revenue was up 10.3% compared to the same quarter last year. Analysts expect that PAREXEL International will post $2.15 EPS for the current fiscal year.

PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.